Agent for the treatment of hypoactive sexual desire disorder in premenopausal women.
The drug is a 5 hydroxytryptamine (5HT) type 1A receptor agonist and 5HT type 2A antagonist.
Oral agent dose 100 mg daily at bedtime.
Studies show the drug increases satisfying sexual events by 0.5 to 1 per month, roughly 10% increase in treatment effect over placebo.
The drug risks include syncope and hypotension which can be increased with the use of CYP3A4 inhibitors including hormonal contraceptive products and alcohol. Flibanserin
Trade name Addyi.
An oral medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD).
The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three.
Side effects include: dizziness, sleepiness, and nausea .
Pregnancy category US: C
Bioavailability 33% with protein binding of 98%.
Metabolism extensive by liver, mainly by CYP3A4 and CYP2C19
Biological half-life ~11 hours.
Excretion via biliary 51%, and kidney 44%
Used for hypoactive sexual desire disorder among women.
Users of flibanserin report a 0.5 increase compared to placebo in the number of times they had satisfying sexual events.
Trials show an increase number of satisfying sexual events and reduced distress related to sexual desire.
Adverse events most commonly reported include: dizziness, nausea, feeling tired, sleepiness, and trouble sleeping.
Drinking alcohol while on flibanserin may result in severely low blood pressure.
Acts as a full agonist in the frontal cortex and the raphe dorsalis.
Acts as only a partial agonist in the CA3 region of the hippocampus.
Various neurotransmitters, sex steroids, and other hormones have important excitatory or inhibitory effects on the sexual response.
Excitatory activity is driven by dopamine and norepinephrine, while inhibitory activity is driven by serotonin.
The balance between these systems is of significance for a normal sexual response.
By modulating serotonin and dopamine activity in certain parts of the brain, it may improve the balance between these neurotransmitter systems in the regulation of sexual response.
Approved for the treatment of premenopausal women with low sexual desire that causes personal distress or relationship difficulties.
Should not be used to treat low sexual desire caused by co-existing psychiatric or medical problems; low sexual desire caused by problems in the relationship; or low sexual desire due to medication side effects.
Patients need to submit a written agreement to abstain from alcohol.
Physicians require online training to get certified, women are not allowed to drink alcohol, the medication has to be taken daily and is costly, about US$800 per month
An oral medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD).
The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three.
Side effects include: dizziness, sleepiness, and nausea .
Pregnancy category US: C
Bioavailability 33% with protein binding of 98%.
Metabolism extensive by liver, mainly by CYP3A4 and CYP2C19
Biological half-life ~11 hours.
Excretion via biliary 51%, and kidney 44%
Used for hypoactive sexual desire disorder among women.
Users of flibanserin report a 0.5 increase compared to placebo in the number of times they had satisfying sexual events.
Trials show an increase number of satisfying sexual events and reduced distress related to sexual desire.
Adverse events most commonly reported include: dizziness, nausea, feeling tired, sleepiness, and trouble sleeping.
Drinking alcohol while on flibanserin may result in severely low blood pressure.
Acts as a full agonist in the frontal cortex and the raphe dorsalis.
Acts as only a partial agonist in the CA3 region of the hippocampus.
Various neurotransmitters, sex steroids, and other hormones have important excitatory or inhibitory effects on the sexual response.
Excitatory activity is driven by dopamine and norepinephrine, while inhibitory activity is driven by serotonin.
The balance between these systems is of significance for a normal sexual response.
By modulating serotonin and dopamine activity in certain parts of the brain, it may improve the balance between these neurotransmitter systems in the regulation of sexual response.
Approved for the treatment of premenopausal women with low sexual desire that causes personal distress or relationship difficulties.
Should not be used to treat low sexual desire caused by co-existing psychiatric or medical problems; low sexual desire caused by problems in the relationship; or low sexual desire due to medication side effects.
Patients need to submit a written agreement to abstain from alcohol.
Physicians require online training to get certified, women are not allowed to drink alcohol, the medication has to be taken daily and is costly, about US$800 per month